Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?-Reference-Cited by-同舟云学术

Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?

Published:2020-08-24 Issue:1 Volume:18 Page:
ISSN:1477-9560
Container-title:Thrombosis Journal
language:en
Short-container-title:Thrombosis J

Author:

Giffard-Quillon Lorine,Desmurs-Clavel Helene,Grange Claire,Jourdy Yohann,Dargaud Yesim^ORCID

Abstract

AbstractRivaroxaban has the most available data to support the use of prothrombin complex concentrates (PCC) as a reversal agent. However, PCC might increase the incidence of thrombotic events by shifting the haemostatic balance towards hypercoagulability. We assessed the in vitro efficacy and safety of three 4-factor PCCs for reversing rivaroxaban anticoagulant effect. Our in vitro finding indicates that 4-factor PCCs at the dose of 25 U.kg− 1 may be sufficient to reverse rivaroxaban anticoagulant effect.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1186/s12959-020-00228-9.pdf

Reference16 articles.

1. Ruff C, Giugliano R, Antman E. Management of bleeding with nonvitamin K antagonists oral anticoagulants in the era of specific reversal agents. Circulation. 2016;134:248–61.

2. Myers B, Webster A. Heavy menstrual bleeding on rivaroxaban - comparison with Apixaban. Br J Haematol. 2017;176:833–5.

3. Connolly, S.J., Milling Jr, T.J., Eikelboom, J.W., Gibson, C.M., Curnutte, J.T., Gold, A., Bronson, M.D., Lu, G., Conley, P.B., Verhamme, P., Schmidt, J., Middeldorp, S., Cohen, A.T., Beyer- Westendorf, J., Albaladejo, P., Lopez-Sendon, J., Goodman, S., Leeds, J., Wiens, B.L., Siegal, D.M., Zotova, E., Meeks, B., Nakamya, J., Lim,W.T. & Crowther, M. (2016). Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med, 375, 1131–1141.

4. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart Rythm association practical guide on the use of the non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93.

5. Deepa R. J. Arachchillage, Sharon Alavian, Jessica Griffin, Kamala Gurung,Richard Szydlo, Nilanthi Karawitage and Mike Laffan Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding British Journal of Haematology, 2019, 184, 808–816.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A small-molecule hemostatic agent for the reversal of direct oral anticoagulant–induced bleeding;Research and Practice in Thrombosis and Haemostasis;2024-05

2. Direct Oral Anticoagulation in Lung Transplant Recipients;Experimental and Clinical Transplantation;2024-04

3. Avatar-based patient monitoring improves information transfer, diagnostic confidence and reduces perceived workload in intensive care units: computer-based, multicentre comparison study;Scientific Reports;2023-04-11

4. Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding;International Journal of Molecular Sciences;2023-04-07

5. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate;Thrombosis Research;2023-03